Skip to main content
micro-community-banner
 
  • Saved

Radiation Therapy Safe for Myeloma Patients Before CAR T-cell...

Radiation Therapy Safe for Myeloma Patients Before CAR T-cell...

Source : https://myelomaresearchnews.com/2020/11/11/radiation-therapy-safe-for-myeloma-patients-before-car-t-cell-infusion-small-study-reports/

Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to be manufactured was found to be safe and did not impact CAR T-cell .....

  • Saved

Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood

Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood

Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/ijlh.13387

Introduction Multiple myeloma (MM) patients with malignant plasma cells (MMPCs) in their bone marrow (BM) and malignant circulating plasma cells (MMCPCs) in the peripheral blood (PB) are an independ...

  • Saved

Emerging agents and regimens for multiple myeloma

Emerging agents and regimens for multiple myeloma

Source : https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00980-5

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory .....

  • Saved

A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism

A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism

Source : https://link.springer.com/article/10.1007/s00277-020-04339-1

Multiple myeloma (MM) is a disease caused by malignant plasma cells, causing free light chain release accompanying the increase in monoclonal immunoglobulin. Cytochrome P450 (CYP) is one of the large .....

Neel Shah, Mark Fesler Commented on a Post
  • Saved

Newest Treatments for Triple-refractory Multiple Myeloma Patients

Triple-refractory multiple myeloma patients are refractory to an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody and represent a major unmet need. Two novel agents are FDA approved for patients treated with at least four prior therapies: selinexor, a small molecule nuclear export inhibitor approved in July 2019 and belantamab mafodotin, an antibody-drug conjugate targeting the B-cell maturation agent (BCMA) approved in August 2020.

In STORM, a pivotal trial evaluating selinexor combined with dexamethasone, the overall response rate (ORR) was 25% and the median duration of response was 3.8 months. Selinexor’s label has warnings and precautions for thrombocytopenia, neutropenia, gastrointestinal toxicity, hyponatremia, infections, neurological toxicity and embryo-fetal toxicity. In the DREAMM-2 pivotal trial, belantamab mafodotin reported an ORR of 32%, a median duration of response of 11 months and a median survival of 14.9 months. The belantamab mafodotin label has a black box warning for ocular toxicity and is only available through a risk evaluation and mitigation strategy (REMS) program. In addition, the belantamab mafodotin label has warnings and precautions for thrombocytopenia, infusion-related reactions and embryo-fetal toxicity.

How do you expect your prescribing practices to change in the future as a result of these recent approvals? Where do you foresee them fitting into your treatment algorithm?

  • Saved

Comparison of Image Quality of Multiple Magnetic Resonance Imagin...: Ingenta Connect

Comparison of Image Quality of Multiple Magnetic Resonance Imagin...: Ingenta Connect

Source : https://www.ingentaconnect.com/contentone/asp/jmihi/2021/00000011/00000002/art00026

Multiple myeloma is a refractory malignant disease characterized by clonal hyper proliferation of plasma cells in the bone marrow microenvironment. In recent years, its incidence has gradually increased and it .....

  • Saved

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma

Source : https://link.springer.com/article/10.1186/s13148-020-00953-y

Multiple myeloma (MM) is a heterogeneous plasma cell malignancy that remains challenging to cure. Global hypomethylation correlates with an aggressive phenotype of the disease, while hypermethylation is observed at particular .....

  • Saved

Maintenance regimens after a second autologous transplant for multiple myeloma

Maintenance regimens after a second autologous transplant for multiple myeloma

Source : https://www.tandfonline.com/doi/abs/10.1080/10428194.2020.1842402?journalCode=ilal20

The authors thank Ritika Halder for assisting with data collection. None of the authors have any conflicts of interest to declare other than the following for Dr Ganguly and Dr .....

  • Saved

Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo

Source : https://pubmed.ncbi.nlm.nih.gov/33147936/

Your access to the NCBI website at www.ncbi.nlm.nih.gov has been temporarily blocked due to a possible misuse/abuse situation involving your site. This is not an indication of a security issue .....

  • Saved

Elevation of miR-302b prevent multiple myeloma cells growth and bone destruction by blocking DKK1 secretion

Elevation of miR-302b prevent multiple myeloma cells growth and bone destruction by blocking DKK1 secretion

Source : https://www.researchsquare.com/article/rs-98086/v1

Background: Myeloma bone disease (MBD) is a severe complication of multiple myeloma (MM) and is mainly attributed to an imbalance between enhanced osteoclast activity and the reducing of osteoblast function. .....